Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 10:51 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 553–576 of 830 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Safety and Pharmacokinetics in Healthy Volunteer Subjects Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of LY3372993 in Healthy Participants and Participants With Alzheimer's Disease (AD)

NCT03720548
View directory record Official record
Conditions
Alzheimer Disease
Interventions
LY3372993, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 85 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
11
States / cities
Long Beach, California • Daytona Beach, Florida • DeLand, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2019 · Synced Oct 15, 2026, 10:51 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics and Safety Study of CTAP101 Capsules in Japanese and Non-Japanese Healthy Subjects and Non-Japanese Healthy Subjects

NCT03660800
View directory record Official record
Conditions
Vitamin D Insufficiency, Secondary Hyperparathyroidism
Interventions
CTAP101 Capsules
Drug
Lead sponsor
OPKO Health, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Sep 30, 2019 · Synced Oct 15, 2026, 10:51 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

To Assess the Pharmacokinetics, Safety and Tolerability of Selumetinib in Renal Impaired Subjects and Healthy Subjects

NCT02063204
View directory record Official record
Conditions
Solid Tumours
Interventions
selumetinib
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jun 30, 2015 · Synced Oct 15, 2026, 10:51 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Safety and PK Study of OLT1177 Capsules

NCT02134964
View directory record Official record
Conditions
Healthy Volunteers
Interventions
OLT1177 Capsules, Placebo Capsules
Drug
Lead sponsor
Olatec Therapeutics, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
College Station, Texas
Source: ClinicalTrials.gov public record
Updated Mar 6, 2015 · Synced Oct 15, 2026, 10:51 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Phase 1 TAK-041 First-in-Human Safety, Tolerability, and Pharmacokinetics Study

NCT02748694
View directory record Official record
Conditions
Healthy Volunteers, Schizophrenia
Interventions
TAK-041, TAK-041 Placebo
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
18 Years to 55 Years
Enrollment
114 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Mar 19, 2021 · Synced Oct 15, 2026, 10:51 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Randomized, Placebo-Controlled, Double-Blind, Ascending Single and Multiple Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BMS-963272 in Healthy Subjects

NCT02327273
View directory record Official record
Conditions
Healthy
Interventions
BMS-963272, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 55 Years
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jul 22, 2015 · Synced Oct 15, 2026, 10:51 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Vitamin E δ-Tocotrienol (VEDT) Single Dose in Healthy Subjects

NCT01446952
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Vitamin E δ-Tocotrienol
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Apr 11, 2016 · Synced Oct 15, 2026, 10:51 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, Pharmacokinetics and Pharmacodynamic of AZD1722 in Healthy Male and Female Japanese Subjects

NCT02176252
View directory record Official record
Conditions
Healthy Volunteer
Interventions
AZD1722, Placebo
Drug
Lead sponsor
Ardelyx
Industry
Eligibility
19 Years to 65 Years
Enrollment
83 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Jun 27, 2014 · Synced Oct 15, 2026, 10:51 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Single Ascending Doses of ABBV-1451 Infusions and Injections in Healthy Adult Participants

NCT07570147
View directory record Official record
Conditions
Healthy Volunteer
Interventions
ABBV-1451, Placebo
Drug · Other
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 60 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Grayslake, Illinois
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 15, 2026, 10:51 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Single Dose Study to Assess Adverse Events and How Oral Icalcaprant Moves Through the Body in Healthy Adult Japanese and Han Chinese Participants

NCT06722417
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Icalcaprant
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Jan 28, 2025 · Synced Oct 15, 2026, 10:51 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study to Evaluate Safety and Pharmacokinetics of GS-4059 (Tirabrutinib) in Healthy Volunteers and Participants With Rheumatoid Arthritis (RA)

NCT02626026
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Tirabrutinib, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
9
States / cities
Sacramento, California • Miami, Florida • Orlando, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2020 · Synced Oct 15, 2026, 10:51 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Study Evaluating HTC-867 in Healthy Young and Elderly Subjects

NCT00827489
View directory record Official record
Conditions
Healthy Subjects
Interventions
HTC-867, Placebo
Drug · Other
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 2, 2009 · Synced Oct 15, 2026, 10:51 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety, Tolerability and PK of NPT520-34 in Healthy Subjects

NCT03954600
View directory record Official record
Conditions
Healthy Volunteers
Interventions
NPT520-34 (125 mg), Placebos (125 mg)
Drug
Lead sponsor
Neuropore Therapies Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 13, 2020 · Synced Oct 15, 2026, 10:51 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Compare the Safety and Drug Levels in Blood When Using Various Forms of GSK189075 Given to Healthy Subjects

NCT00559884
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Diabetes Mellitus, Type 2
Interventions
GSK189075 (Modified and immediate release formulations)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2007
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 4, 2012 · Synced Oct 15, 2026, 10:51 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

A Trial to Evaluate the Safety Tolerability and Pharmacokinetics of B1344 by Subcutaneous Injection in Healthy Subjects

NCT05655221
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis
Interventions
B1344, Placebo
Drug · Other
Lead sponsor
Tasly Biopharmaceuticals Co., Ltd.
Industry
Eligibility
18 Years to 55 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Dec 19, 2022 · Synced Oct 15, 2026, 10:51 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Monotherapy Versus Placebo Over 14 or 17 Days in Healthy and Hepatitis C Infected Adults

NCT00439959
View directory record Official record
Conditions
Hepatitis C, Chronic, Hepatitis C
Interventions
GSK625433/placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 4, 2012 · Synced Oct 15, 2026, 10:51 PM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, and Pharmacokinetics of BGB-23339 in Healthy Japanese and Caucasian Subjects

NCT05387668
View directory record Official record
Conditions
Healthy Volunteers
Interventions
BGB-23339, Placebo
Drug
Lead sponsor
BeiGene
Industry
Eligibility
18 Years to 55 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Dec 16, 2022 · Synced Oct 15, 2026, 10:51 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Short and Long Intravenous Infusion Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of BMS-962212 in Healthy Subjects

NCT03197779
View directory record Official record
Conditions
Thrombosis
Interventions
BMS-962212, Aspirin, Placebo
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 45 Years
Enrollment
691 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
3
States / cities
Cypress, California • Glendale, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 15, 2026, 10:51 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of LY3200327 in Healthy Participants

NCT02595736
View directory record Official record
Conditions
Healthy
Interventions
Placebo (SC), LY3200327 (SC), LY3200327 (IV), Placebo (IV)
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Sep 12, 2016 · Synced Oct 15, 2026, 10:51 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1, Study to Evaluate HTI-2088 Tablet

NCT03203811
View directory record Official record
Conditions
Diabetes
Interventions
HTI-2088, Placebo
Drug
Lead sponsor
Hengrui Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 14, 2017 · Synced Oct 15, 2026, 10:51 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABBV-1088 Oral Dose in Healthy Adult Participants.

NCT06414798
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Drug: ABBV-1088, Drug: Placebo for ABBV-1088
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Grayslake, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 19, 2025 · Synced Oct 15, 2026, 10:51 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess Adverse Events and How Single and Multiple Ascending Doses of ABBV-903 Move Through the Body in Healthy Adults

NCT05691699
View directory record Official record
Conditions
Healthy Volunteer
Interventions
ABBV-903, Placebo for ABBV-903, Itraconazole
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
104 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Grayslake, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 30, 2023 · Synced Oct 15, 2026, 10:51 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment of Ph+ CML Resistant/Intolerant to ≥3 Prior CML Therapies

NCT02629692
View directory record Official record
Conditions
Healthy (For Part A), Chronic Myeloid Leukemia (for Part B and C)
Interventions
Vodobatinib (K0706) capsules
Drug
Lead sponsor
Sun Pharma Advanced Research Company Limited
Industry
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
8
States / cities
Downey, California • Los Angeles, California • Jacksonville, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Oct 15, 2026, 10:51 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

GSK1349572 Hepatic Impairment Study

NCT01231529
View directory record Official record
Conditions
Healthy Subjects, Hepatic Impairment, Infection, Human Immunodeficiency Virus, HIV Infections
Interventions
GSK1349572
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 70 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 31, 2019 · Synced Oct 15, 2026, 10:51 PM EDT